1h Free Analyst Time
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Pipeline Review, H1 2018Speak directly to the analyst to clarify any post sales queries you may have.
Summary:
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) pipeline Target constitutes close to 8 molecules. The latest report Ileal SodiumBile Acid Cotransporter - Pipeline Review, H1 2018, outlays comprehensive information on the Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Ileal Sodium/Bile Acid Co-transporter is encoded by SLC10A2 gene. It plays a critical role in the sodium-dependent reabsorption of bile acids from the lumen of the small intestine and cholesterol metabolism. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 3, 1 and 3 respectively. Report covers products from therapy areas Gastrointestinal, Dermatology, Genetic Disorders and Metabolic Disorders which include indications Non-Alcoholic Steatohepatitis (NASH), Cholestasis, Primary Sclerosing Cholangitis, Alagille Syndrome, Primary Biliary Cirrhosis, Progressive Familial Intrahepatic Cholestasis, Pruritus, Biliary Atresia, Liver Diseases and Type 2 Diabetes.
Furthermore, this report also reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope:
- The report provides a snapshot of the global therapeutic landscape for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)
- The report reviews Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) targeted therapeutics
Reasons for Purchase:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
IntroductionReport Coverage
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Overview
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Companies Involved in Therapeutics Development
Albireo Pharma Inc
CJ HealthCare Corp
GlaxoSmithKline Plc
Shire Plc
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Drug Profiles
A-4250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CJ-14199 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit IBAT for Liver and Metabolic Diseases - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
elobixibat - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GSK-2330672 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
maralixibat chloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-435 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
volixibat potassium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Dormant Products
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Discontinued Products
Ileal Sodium/Bile Acid Cotransporter (Apical Sodium Dependent Bile Acid Transporter or ASBT or Sodium/Taurocholate Cotransporting Polypeptide Ileal or Solute Carrier Family 10 Member 2 or SLC10A2) - Product Development Milestones
Featured News & Press Releases
May 28, 2018: PIII Clinical Study Data on Chronic Constipation Treatment “GOOFICE 5mg Tablet” Will Be Presented at DDW2018
May 16, 2018: Albireo Enrolls First Patient in Phase 3 PFIC Trial of A4250
Apr 19, 2018: World's First Bile Acid Transporter Inhibitor GOOFICE 5mg Tablet Launched in Japan
Apr 19, 2018: Albireo to Present Data from Two Studies on Cholestatic Liver Disease at the 51st ESPGHAN Annual Meeting
Apr 14, 2018: Albireo Reports Data on Pharmacodynamic Marker for A4250 in Children with Cholestatic Liver Disease at the International Liver Congress 2018
Mar 28, 2018: Albireo to Present Clinical Data on A4250 at The International Liver Congress 2018
Jan 19, 2018: New drug approval of bile acid transporter inhibitor “GOOFICE 5mg Tablet ”for chronic constipation was obtained in Japan
Oct 20, 2017: Final Results of Albireo's Phase 2 Study of A4250 in Children with Cholestatic Liver Disease Presented at The Liver Meeting 2017
Oct 03, 2017: Final Results of Albireos Phase 2 Study of A4250 in Children with Cholestatic Liver Disease to be Presented at The Liver Meeting 2017
Sep 26, 2017: EMA's Pediatric Committee Agrees to Albireo's A4250 Pediatric Investigation Plan
May 18, 2017: Albireo Announces Plans for Phase 3 Clinical Program of A4250 in Patients with PFIC
May 16, 2017: Albireo Announces Two New U.S. Patents Allowed for A4250 with Term into 2031
Apr 27, 2017: Albireo Announces Elobixibat Data from Japan to be Presented at DDW 2017
Apr 22, 2017: Promising Pediatric Data for Albireo's A4250 to be Presented at The International Liver Congress 2017
Apr 05, 2017: EASL Selects Albireo's A4250 Data for Late Breaker Presentation
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Albireo Pharma Inc, H1 2018
Pipeline by CJ HealthCare Corp, H1 2018
Pipeline by GlaxoSmithKline Plc, H1 2018
Pipeline by Shire Plc, H1 2018
Dormant Projects, H1 2018
Discontinued Products, H1 2018
List of Figures
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Albireo Pharma Inc
- CJ HealthCare Corp
- GlaxoSmithKline Plc
- Shire Plc
